EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like receptor 7 agonist ruzotolimod

Qiudi Jiang iD, Yuchen Zhang, Dan Duan, Sylvie Retout iD, Ruchi Upmanyu, Katerina Glavini iD, Miriam Triyatni iD, Yonghong Zhu iD, Joseph F Grippo, Yuyan Jin iD

Clinical and Translational Science · 2024

DOI: 10.1111/cts.13896 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Qiudi Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Roche Innovation Center, Shanghai, China. Hauptthemen laut MEDLINE: Toll-Like Receptor 7, Healthy Volunteers, Hepatitis B, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ruzotolimod (Toll‐like receptor 7 (TLR7) agonist, RG7854) is an oral, small molecule immuno‐modulator activating the TLR 7 and is being evaluated in patients with CHB. As with other TLR7 agonists, the study drug‐related adverse events of flu‐like symptoms have been reported in some participants during phase I studies with ruzotolimod. An exploratory analysis of the relationship between pharmacokinetic (PK)/pharmacodynamic (PD) and flu‐like symptoms was performed in participants from two phase I studies including both healthy volunteers and NUC‐suppressed CHB patients who received either single or multiple ascending doses of orally administered ruzotolimod. Linear and logistic regression were used to explore potential relationships between dose, flu‐like symptoms, PK, and PD. Generalized linear regression was performed to predict the probability of flu‐like symptoms of all intensities at different RO7011785 (the active metabolite of the double prodrug ruzotolimod) PK exposure. This analysis showed that single or multiple doses of ruzotolimod at ⩾100 mg, the immune PD (IFN‐α, neopterin, IP‐10, and the transcriptional expression of ISG15, OAS‐1, MX1, and TLR7) responses increase with the RO7011785 PK exposure, which increases linearly with the doses from 3 mg to 170 mg of ruzotolimod. The analysis also showed that the probability of flu‐like symptoms occurrence increases with PD responses (IFN‐α and IP‐10). Dose reduction of ruzotolimod can be an effective way to reduce the magnitude of PD response, thus reducing the probability of study drug‐related flu‐like symptoms occurrence at all intensity in the participants who are highly sensitive to PD activation and intolerant to flu‐like symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 7Healthy VolunteersHepatitis B, ChronicHumansMaleAdultFemaleMiddle AgedYoung AdultAntiviral AgentsInfluenza, HumanDose-Response Relationship, DrugAdolescentAdministration, OralOrganic Chemicals

Substanzen

Toll-Like Receptor 7TLR7 protein, humanAntiviral AgentsRO7020531Organic Chemicals

Autor:innen und Institutionen

  • Roche Innovation Center, Shanghai, China.
  • Roche Innovation Center, Basel, Switzerland.
  • Roche Innovation Center, Welwyn, UK.
  • Roche Innovation Center, New York, New York, USA.

ORCID-Profile: Qiudi Jiang, Sylvie Retout, Katerina Glavini, Miriam Triyatni, Yonghong Zhu, Yuyan Jin

Zitieren

APA

Jiang, Q., Zhang, Y., Duan, D., Retout, S., Upmanyu, R., Glavini, K., Triyatni, M., Zhu, Y., Grippo, J. F., & Jin, Y. (2024). Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like receptor 7 agonist ruzotolimod. Clinical and Translational Science. https://doi.org/10.1111/cts.13896

Vancouver

Jiang Q, Zhang Y, Duan D, Retout S, Upmanyu R, Glavini K, et al. Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like receptor 7 agonist ruzotolimod. Clinical and Translational Science. 2024. doi:10.1111/cts.13896

BibTeX
@article{Jiang2024,
  author = {Jiang, Qiudi and Zhang, Yuchen and Duan, Dan and Retout, Sylvie and Upmanyu, Ruchi and Glavini, Katerina and Triyatni, Miriam and Zhu, Yonghong and Grippo, Joseph F and Jin, Yuyan},
  title = {Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like receptor 7 agonist ruzotolimod},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.13896}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche